| 前收盘价格 | 58.91 |
| 收盘价格 | 58.99 |
| 成交量 | 305,268 |
| 平均成交量 (3个月) | 1,670,395 |
| 市值 | 10,748,232,704 |
| 预期市盈率 (P/E Forward) | 5.00 |
| 价格/销量 (P/S) | 2.58 |
| 股市价格/股市净资产 (P/B) | 3.23 |
| 52周波幅 | |
| 利润日期 | 7 Feb 2025 - 11 Feb 2025 |
| 营业毛利率 | -9.34% |
| 营业利益率 (TTM) | -6.94% |
| 稀释每股收益 (EPS TTM) | -2.28 |
| 季度收入增长率 (YOY) | 4.20% |
| 总债务/股东权益 (D/E MRQ) | 139.67% |
| 流动比率 (MRQ) | 2.51 |
| 营业现金流 (OCF TTM) | 399.00 M |
| 杠杆自由现金流 (LFCF TTM) | 364.50 M |
| 资产报酬率 (ROA TTM) | -0.18% |
| 股东权益报酬率 (ROE TTM) | -11.19% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看跌 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看跌 | 混合的 | |
| 股票 | Catalent, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-0.5
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | 0.0 |
| 平均 | -0.50 |
|
Catalent is a contract development and manufacturing organization, or CDMO. It operates under four segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. Catalent derives its revenues primarily from long-term supply agreements with pharmaceutical customers. The company provides a range of development and manufacturing solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products throughout the entire life cycle of a product from the drug development process to commercial supply. Catalent has over 50 facilities across four continents. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Core |
| 内部持股比例 | 0.50% |
| 机构持股比例 | 87.89% |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合